Kymera Therapeutics Initiates KT-621 Phase 2b Clinical Trial

Written by Emily J. Thompson, Senior Investment Analyst

Updated: 2h ago

0mins

Kymera Therapeutics announced that it recently initiated dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe eosinophilic asthma. The Company expects to report data from the BREADTH trial in late-2027.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

Sign up now to unlock expert insights and stay one step ahead of the market trends.

KYMR

$71.94+Infinity%1D

Analyst Views on KYMR

Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 116.30 USD with a low forecast of 90.00 USD and a high forecast of 138.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

22 Analyst Rating

21 Buy

1 Hold

0 Sell

Strong Buy

Current: 71.160

Low

90.00

Averages

116.30

High

138.00

Current: 71.160

Low

90.00

Averages

116.30

High

138.00

Barclays

Eliana Merle

Overweight

initiated

$119 -> $133

2026-01-27

New

Reason

Barclays

Eliana Merle

Price Target

$119 -> $133

AI Analysis

2026-01-27

New

initiated

Overweight

Reason

Barclays analyst Eliana Merle assumed coverage of Kymera Therapeutics with an Overweight rating and price target of $133, up from $119. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

Wolfe Research

Outperform -> Peer Perform

downgrade

2026-01-06

Reason

Wolfe Research

Price Target

2026-01-06

downgrade

Outperform -> Peer Perform

Reason

Wolfe Research downgraded Kymera Therapeutics to Peer Perform from Outperform.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KYMR

Unlock Now

About KYMR

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.